Fecal microbiota transplants may enhance patients’ response to immunotherapy, but experts caution that the latest data remain proof-of-concept and far from practice-changing.

Please provide your email address to receive an email when new articles are posted on . Fecal microbiota-based therapies are becoming more prevalent in the management of Clostridioides difficile ...

Fecal microbiota transplant was noninferior to vancomycin as the initial treatment for C. diff in a randomized, open-label trial. Transplant showed slightly higher cure rates without recurrence and ...

Adding fecal microbiota therapy to standard care for steroid-ineligible severe alcoholic-associated hepatitis appeared safe and effective in a small randomized trial from India. Survival at 90 days ...

A therapy using fecal matter to combat a bad bug in the gut will now be regulated by the federal government, to the consternation of some physicians. The bug is Clostridium difficile, or C. diff, and ...

Clinical cure and no disease recurrence within 60 days without additional treatment was observed in 66.7% of 51 patients receiving FMT vs 61.2% of 49 patients receiving vancomycin. HealthDay News — ...

Swiss pharma giant Roche on Monday said it would buy Telavant, an immunology company developing a promising treatment for inflammatory bowel disease, in a deal worth more than $7 billion, as the ...